Description
Rocilinostat is an orally bioavailable histone deacetylase 6 (HDAC6) inhibitor with potential antineoplastic activity. It selectively targets and binds to HDAC6, thereby disrupting the Hsp90 protein chaperone system through hyperacetylation of Hsp90 and preventing the subsequent aggresomal protein degradation. Compared to non-selective HDAC inhibitor, Rocilinostat is able to reduce the toxic effects on normal, healthy cells